Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab ± guadecitabine in melanoma and NSCLC resistant to anti-PD-1/PD-L1
2019-002986-36Phase 2Active
- Sponsor
- Fondazione NIBIT
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in melanoma, non-small cell lung cancer (NSCLC) and Neoplasm comparing Nivolumab + ipilimumab + guadecitabine with Nivolumab + ipilimumab (2 arms). Primary endpoint: Immune-related objective response rate. Started Aug 2021; status: active.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)Neoplasm
Beyond the preview
Go deeper on 2019-002986-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002986-36.